EQ

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.

Wall Street analysts forecast EQ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EQ is 0.50 USD with a low forecast of 0.50 USD and a high forecast of 0.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Equillium Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Equillium Inc. EPS for the last quarter amounts to -0.24 USD, increased 200.00 % YoY.

Equillium Inc (EQ) has 35 emplpoyees as of July 30 2025.

Today EQ has the market capitalization of 13.74M USD.